Dr. John Cullity Appointed Chairman of HaemaLogiX

The Board of HaemaLogiX Ltd has appointed non-executive director, Dr, John Cullity, as Chairman of the Company to hold office through the next phase of the Company transformation, which was initiated earlier this year with the announcement of our new CEO.

Dr. Cullity’s appointment is effective as of 4 January 2024.

The Board are pleased to advise, that outgoing Chairman, Bryce Carmine, will remain active in the company, retaining his role of non-executive director.

Mr. Carmine stated, “It has been a huge honour being the HaemaLogiX Chairman since the inception of the Company. I’m proud of what we have achieved to date and have every confidence in the direction the Company is taking”.

Dr. Cullity has been on the HaemaLogiX board since 2014 as a founding shareholder and brings 20+ years of industry and commercial markets experience. In addition to his platform education as a haematologist-oncologist, John was a strategic advisor at Torreya, delivering corporate strategy for M&A, partnering, financing and has led buy-side transactions in oncology and diabetes. Earlier in his career, John worked with Sanofi in the US as Head of Strategic Pricing & Reimbursement.

“I’m thrilled on being appointed as Chairman and look forward to working with the Board and team to continue the great work that has been done date” Dr. Cullity said.

HaemaLogiX Non-Executive Director Alan Liddle said: “John’s experience and insightfulness has been a great asset over these years, and we welcome his direction on the board as Chairman and on behalf of the Board, we sincerely thank Bryce for his tenure as Chairman and look forward to his continued input as a non-executive member.”